Search

Displaying results 4751 - 4760 of 5449 in total
  1. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  2. Drug

    3-amino-5-phenylpentane

    go.drugbank.com/drugs/DB02869
    Experimental

    These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K

  3. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  4. Drug

    mRNA-3927

    go.drugbank.com/drugs/DB17669
    Investigational

    Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.[L45998]

  5. Drug

    Ofirnoflast

    go.drugbank.com/drugs/DB21679
    Investigational

    Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da.

  6. Drug

    Zanapezil

    go.drugbank.com/drugs/DB04859
    Experimental

    Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.

  7. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [L48141] It has also been investigated alongside [pembrolizumab] for the treatment of pancreatic cancer.[A261481]

  8. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex

    Products: ACARBOSA 50 MG, ACARBOSA 100 MG
  9. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]

  10. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.